Description: Vectus Biosystems Limited is engaged in medical Research and Development. The Company's drug candidates can be orally administered. The Company's primary lead compound, VB0004, has been shown to be both anti-hypertensive and anti-fibrotic in the heart and kidneys. Using its platform technology, the Company has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), as well as pulmonary fibrotic diseases. Accugen is a platform, developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions, which measures the amount of Deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in a sample. It identifies drug targets with specific activity in the heart, kidneys, lungs and liver.
Home Page: www.vectusbiosystems.com.au
VBS Technical Analysis
3-11 Primrose Avenue
Rosebery,
NSW
2018
Australia
Phone:
61 2 9381 1000
Officers
| Name | Title |
|---|---|
| Dr. Karen Annette Duggan | CEO & Exec. Director |
| Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin | Company Sec. |
| Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC | Consultant |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 32.6829 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |